A5083552205- Prostate Cancer Treatment and Research
- Epigenetics and DNA Methylation
- Prostate Cancer Diagnosis and Treatment
- Cancer-related gene regulation
- RNA modifications and cancer
- Histone Deacetylase Inhibitors Research
- Bladder and Urothelial Cancer Treatments
- Cancer Genomics and Diagnostics
- Cannabis and Cannabinoid Research
- GABA and Rice Research
- Cancer Research and Treatments
- Ovarian cancer diagnosis and treatment
- Molecular Biology Techniques and Applications
- Cancer, Hypoxia, and Metabolism
- Cancer-related molecular mechanisms research
- Global Cancer Incidence and Screening
- Cancer Immunotherapy and Biomarkers
- Ferroptosis and cancer prognosis
- Legume Nitrogen Fixing Symbiosis
- MicroRNA in disease regulation
- Genetic and Environmental Crop Studies
- Animal Genetics and Reproduction
- Urologic and reproductive health conditions
- Polyamine Metabolism and Applications
- Urological Disorders and Treatments
University College Dublin
2012-2024
University of California, San Francisco
2021
Southern Medical University Shenzhen Hospital
2021
Trinity College Dublin
2008-2020
Molecular Medicine Ireland
2010-2018
National University of Ireland
2017
St. James's Hospital
2007-2015
In-Q-Tel
2012
Institute of Molecular Medicine
2011
Molecular Oncology (United States)
2011
Point mutations result from errors made during DNA replication or repair, so they are usually expected to be homogeneous across all regions of a genome. However, we have found region chloroplast in plants related sweetpea (Lathyrus) whose local point mutation rate is at least 20 times higher than elsewhere the same molecule. There very few precedents for such heterogeneity any genome, and suspect that hypermutable may subject an unusual process as repeated breakage repair. The 1.5 kb long...
While conventional cancer treatments, such as surgery, radiotherapy and chemotherapy, have been combined for decades in an effort to treat patients, the emergence of novel fields research led a renewed interest combining treatments with more innovative approaches. The realisation that progression is not exclusively due changes epithelial cells, but also involves tumour microenvironment, has opened new avenues combination treatments. Here we discuss use therapies presented at 55th Irish...
Liquid biopsies that noninvasively detect molecular correlates of aggressive prostate cancer (PCa) could be used to triage patients, reducing the burdens unnecessary invasive biopsy and enabling early detection high-risk disease. DNA hypermethylation is among earliest most frequent aberrations in PCa. We investigated accuracy a six-gene methylation panel (Epigenetic Cancer Prostate Test Urine [epiCaPture]) at detecting PCa, high-grade (Gleason score greater than or equal 8) (D'Amico Risk...
Classifying indolent prostate cancer represents a significant clinical challenge. We investigated whether integrating data from different omic platforms could identify biomarker panel with improved performance compared to individual alone. DNA methylation, transcripts, protein and glycosylation biomarkers were assessed in single cohort of patients treated by radical prostatectomy. Novel multiblock statistical integration approaches used deal missing modelled via stepwise multinomial logistic...
Objectives To analyse the clinical utility of a prediction model incorporating both information and novel biomarker, p2 PSA , in order to inform decision for prostate biopsy an Irish cohort men referred cancer assessment. Patients Methods Serum isolated from 250 three tertiary referral centres with pre‐biopsy blood draws was analysed total prostate‐specific antigen ( ), free fPSA ) . From this, Prostate Health Index PHI score calculated = (p2 / )*√ tPSA ). The men's used derive their risk...
To develop a risk classifier using urine-derived extracellular vesicle (EV)-RNA capable of providing diagnostic information on disease status prior to biopsy, and prognostic for men active surveillance (AS).Post-digital rectal examination EV-RNA expression profiles (n = 535, multiple centres) were interrogated with curated NanoString panel. A LASSO-based continuation ratio model was built generate four prostate urine (PUR) signatures predicting the probability normal tissue (PUR-1), D'Amico...
The inclusion criterion for active surveillance (AS) is low- or intermediate-risk prostate cancer. predictive value of the presence a suspicious lesion at magnetic resonance imaging (MRI) time insufficiently known.To evaluate percentage patients needing treatment stratified by absence baseline MRI.A retrospective analysis data from multicentric AS GAP3 Consortium database was conducted. criteria were men with grade group (GG) 1 GG 2 cancer combined prostate-specific antigen <20 ng/ml. We...
Aberrant activation of Wnts is common in human cancers, including prostate. Hypermethylation associated transcriptional silencing Wnt antagonist genes SFRPs (Secreted Frizzled-Related Proteins) a frequent oncogenic event. The significance this not known prostate cancer. objectives our study were to (i) profile signaling related gene expression and (ii) investigate methylation Using TaqMan Low Density Arrays, we identified 15 with significantly altered cancer; the majority which upregulated...
Prevention of unnecessary biopsies and overtreatment indolent disease remains a challenge in the management prostate cancer. Novel non-invasive tests that can identify clinically significant (intermediate-risk high-risk) diseases are needed to improve risk stratification monitoring cancer patients. Here, we investigated panel six DNA methylation biomarkers urine samples collected post-digital rectal exam from patients undergoing biopsy, for their utility guide decision making diagnostic...
Abstract Background Disease progression and therapeutic resistance are hallmarks of advanced stage prostate cancer (PCa), which remains a major cause cancer-related mortality around the world. Longitudinal studies, coupled with use liquid biopsies, offer potentially new minimally invasive platform to study dynamics tumour progression. Our aim was investigate personal DNA methylomic profiles metastatic PCa (mPCa) patients, during disease therapy administration. Results Forty-eight plasma...
Abstract Background Glycosylation, one of the most fundamental post-translational modifications, is altered in cancer and subject part, to epigenetic regulation. As there are many epigenetic-targeted therapies currently clinical trials for treatment a variety cancers, it important understand impact epi-therapeutics have on glycosylation. Results Ovarian triple negative breast cells were treated with DNA methyltransferase inhibitor, 5-AZA-2-deoxycytidine (5-AZA-dC). Branching sialylation...
Abstract Resistance to platinum‐based chemotherapy is the major cause of death from high‐grade serous ovarian cancer (HGSOC). We hypothesise that detection specific DNA methylation changes may predict platinum resistance in HGSOC. Using a publicly available “discovery” dataset we examined epigenomic and transcriptomic alterations between primary platinum‐sensitive (n = 32) recurrent acquired drug resistant HGSOC 28) identified several genes involved immune chemoresistance‐related pathways....
Gemcitabine is indicated in combination with cisplatin as first-line therapy for solid tumours including non-small cell lung cancer (NSCLC), bladder and mesothelioma. an analogue of pyrimidine cytosine functions anti-metabolite. Structurally, however, gemcitabine has similarities to 5-aza-2-deoxycytidine (decitabine/Dacogen®), a DNA methyltransferase inhibitor (DNMTi). NSCLC, mesothelioma prostate lines were treated decitabine gemcitabine. Reactivation epigenetically silenced genes was...
IGFBP7 belongs to a family of insulin-like growth factor-1 regulatory binding proteins. hypermethylation is associated with its down-regulation in various carcinomas. In prostate cancer has been widely reported but our knowledge the mechanisms behind this event are unknown. We performed denaturing high performance liquid chromatography screening and validation strategy profile methylation status cancer.We combined bisulfite sequencing examine panel cell lines. Quantitative specific...
Promoter hypermethylation is central in deregulating gene expression cancer. Identification of novel methylation targets specific cancers provides a basis for their use as biomarkers disease occurrence and progression. We developed an silico strategy to globally identify potential promoter prostate cancer by screening 5′ CpG islands 631 genes that were reported downregulated A virtual archive 338 was produced. One candidate, IGFBP3, selected investigation, along with...